The concept of exploiting the immune system to treat cancer forms the basis of immuno-oncology. Since its birth in the late 1800s, immuno-oncology, or cancer immunotherapy, has come a long way. With better understanding of the complex relationship between tumor and the immune system, we have been able to explore and develop various modalities of anticancer therapies. In this review, we summarize the main strategies of immunotherapy that are available today: monoclonal antibodies, anticancer vaccines, cytokines, and adoptive T-cell therapy. We also highlight the unique set of adverse effects associated with modern immunotherapy and propose nonsteroidal immunomodulators and anticytokine antibodies as treatment options for toxicities. The future of immuno-oncology is discussed, including combination therapy, drug-antibody conjugates, epigenetic drugs, using nanoparticles for drug delivery, new antigen discovery, and developing biomarkers to assess treatment responses. A data search was conducted using PubMed and included studies published through November 1, 2017. Search terms used include cancer immunotherapy, pembrolizumab, ipilimumab, nivolumab, PD-1 inhibitors, PD-L1 inhibitors, checkpoint inhibitors, anticancer vaccines, TVEC, and adoptive cell therapy. I n recent times, immunotherapy has emerged as a promising treatment option in medicine. Immunotherapy modifies the immune system by augmentation or suppression of immune responses to obtain a desired effect. As such, immunomodulators have found applications in various fields of medicine, such as dermatology, rheumatology, immunology, and oncology. This review summarizes the various uses of immunotherapy in oncology, discusses practical considerations, and proposes possible applications in the future.
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The immune system and cancer have a complex relationship such that advanced cancer causes immune suppression, and an immunosuppressed state can predispose to cancer. Tumors use various mechanisms to evade antitumor responses. When the immune system recognizes a tumor, it destroys the cells it can from the tumor. This forms the elimination phase, also called the phase of immune surveillance. The tumor cells that escape the initial immunosurveillance enter the phase of equilibrium, during which these cells undergo mutations to evade immune response. These tumor cells are said to undergo "cancer immunoediting," during which they are continuously groomed with properties/mutations to bypass immune-based killing. By the time tumor cells enter the escape phase they have accumulated enough mutations to elude the immune system and grow unchallenged. 1 Most of the time, tumor cells downregulate major histocompatibility complex expression, thus reducing their presentation to the immune system. Tumors also use the "brakes" of the immune system, such as programmed cell death 1 (PD-1) and cytotoxic T-lymphocyteeassociated protein 4 (CTLA-4), to turn down immune responses. 2, 3 Some tumors attract myeloid-derived suppressor cells and interfere with their maturation, thus reducing antitumor immunity. Also, regulatory T cells dampen immune responses against tumors. 4 The idea of harnessing the immune response to fight cancer dates back to the times of Dr William Coley. Since then we have made many attempts to use our immune system in immunooncology.
ERA OF ANTIBODIES
It was only in the 1970s that monoclonal antibodies for specific targets were developed. Monoclonal antibodies bind to the antigens expressed on the tumor cells and bring about their action. They exert antitumoral responses by 1 of these mechanisms:(1) direct cytotoxicity by inducing apoptosis or downregulating signals of cell survival; (2) delivery of cytotoxic and radiotherapeutic agents; (3) antibodydependent cell-mediated cytotoxicity and complement-dependent cytotoxicity; (4) targeting growth factors and vasculature, thereby preventing tumor growth; or (5) targeting the supporting junctions with stromal cells or microenvironment. [5] [6] [7] IMMUNE CHECKPOINT BLOCKADE A member of the CD28:B7 immunoglobulin family, CTLA-4 functions as an immune checkpoint. On binding to B7 present on the antigen-presenting cells, CTLA-4 downregulates T-cell activation. 8 It plays an important role in preventing autoimmunity by preventing excessive T-cell activation. Figure 1 explains the action of CTLA inhibitors. Ipilimumab is an antieCTLA-4 antibody that causes blockade of CTLA-4, resulting in prolonged T-cell activation, proliferation, and antitumor response.
Ipilimumab in Melanoma
In 2011, the Food and Drug Administration (FDA) approved ipilimumab, a CTLA-4 inhibitor, as first-line therapy for metastatic melanoma based on phase 3 trials. In the phase 3 trial conducted by Hodi et al, 9 676 patients with melanoma were enrolled: 403 received ipilimumab 3 mg/kg plus glycoprotein 100 peptide vaccine, 136 received only the vaccine, and 137 patients received only ipilimumab. The median overall survival (OS) of patients in the ipilimumab group was 10 months vs 6.4 months in those who received only the vaccine. There was no difference in the OS between the 2 ipilimumab groups. 9 Another phase 3 trial consisting of 502 patients compared ipilimumab 10 mg/kg plus dacarbazine vs placebo plus dacarbazine. The OS was increased in the ipilimumab group compared with the placebo group (11.2 vs 9.1 months). 10 After the success of adjuvant ipilimumab in a metastatic setting, a trial was conducted comparing adjuvant ipilimumab 10 mg/kg with placebo in patients with resected stage III melanoma. Adjuvant ipilimumab was associated with increased relapse-free survival (RFS) (hazard ratio, 0.75; median RFS, 26.1 vs 17.1 months). These results subsequently led to the FDA approval of the drug in an adjuvant setting. 11 
Ipilimumab in Renal Cell Carcinoma
Another study assessed the combination of nivolumab and ipilimumab vs sunitinib in more than 1000 patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). The objective response (OR) and progression-free survival (PFS) rates were higher in the combination immunotherapy group in patients with intermediate or poor risk. However, in patients at favorable risk, the OR and PFS rates were higher in patients who received sunitinib. 12 
Ipilimumab in Hematologic Malignancies
The efficacy of ipilimumab was studied in patients with hematologic malignancies who had relapsed after an allogenic transplant. Patients were initially treated with 3 mg/kg every 3 weeks, and then the dose was escalated to 10 mg/kg every 3 weeks. Of the 28 patients who were assessed, 11 had lymphoma. Although no ARTICLE HIGHLIGHTS d The various modalities of immuno-oncology are monoclonal antibodies, anticancer vaccines, cytokines, and adoptive T-cell therapy.
d Immunotherapy is associated with a unique range of adverse effects involving the skin, gastrointestinal system, endocrine organs, respiratory system, bones, and joints.
d Immune-related adverse effects are managed with corticosteroids and additional immunosuppression (biologicals) depending on the grade of toxicity.
d Combinations of checkpoint inhibitors with other checkpoint inhibitors/chemotherapeutic agents/epigenetic drugs are being increasingly experimented with in the clinic.
response was seen in patients receiving low-dose ipilimumab, of 22 patients who received a dose of 10 mg/kg, 5 (23%) had a complete response, 2 (9%) had a partial response, and 6 (27%) had a decreased tumor burden. 13 
Ipilimumab in Prostate Cancer
In a randomized phase 3 trial enrolling 799 patients, ipilimumab was compared with placebo after radiotherapy in patients with metastatic castrationresistant prostate cancer that had progressed after docetaxel chemotherapy. There was no significant difference in OS in both groups; however, ipilimumab displayed antitumor activity that warrants further investigation. 14 
Ipilimumab in Lung Cancer
A recent phase 3 trial reported that the addition of ipilimumab to first-line chemotherapy did not prolong OS compared with chemotherapy alone in patients with advanced squamous nonesmall cell lung cancer (NSCLC).
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PROGRAMMED CELL DEATH INHIBITORS
Programmed cell death 1 is an immune checkpoint belonging to the CD28/CTLA-4 receptor family. It binds to 2 known ligands: programmed death ligand-1 (PD-L1) and PD-L2. Once PD-1 binds to PD-L1, it downregulates T-cell functioning. Inhibitors of PD-1 and PD-L1 are being used in various malignancies. 16, 17 Figure 2 explains the action of antiePD-1 and antiePD-L1 blockers. Table 1 summarizes the FDA-approved checkpoint inhibitor monoclonal antibodies.
PD-1 Inhibitors in Melanoma
In a phase 3 trial, pembrolizumab was compared in 2 different doses with ipilimumab. There were 834 patients with melanoma enrolled in the study and divided in a 1:1:1 ratio into groups receiving pembrolizumab 10 mg/kg every 2 weeks or 3 weeks and ipilimumab 3 mg/kg every 3 weeks. The 6-month PFS rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for the ipilimumab group. Efficacy was similar in the 2 pembrolizumab groups; the OR rate was 33% with pembrolizumab and 12% with ipilimumab. 18 Nivolumab is another FDA-approved antiePD-1 antibody. In a phase 3 trial of patients with metastatic melanoma, nivolumab was compared with chemotherapy (investigators' choice). The OR rate was 32% in the nivolumab group compared with 11% in the chemotherapy group. 19 In another phase 3 trial, nivolumab alone was compared with nivolumab plus ipilimumab and ipilimumab alone. The OR rate with nivolumab was 43.7%, with combination therapy was 57.6%, and with ipilimumab monotherapy was 19%. 20 In 2015, the combination of nivolumab and ipilimumab was approved for advanced melanoma.
PD-1/PD L-1 Inhibitors in Lung Cancer
Reck et al, 21 in a randomized controlled phase 3 trial, compared the efficacy of pembrolizumab with that of chemotherapy. Of 305 patients with NSCLC included in the study, 154 received pembrolizumab 200 mg for 3 weeks or chemotherapy. The group taking pembrolizumab had significantly longer PFS (10.3 months vs 6 months). In the pembrolizumab group, there were fewer grade 3 adverse reactions and a higher overall response rate. 21 Based on these results, the FDA approved pembrolizumab as a frontline PD-1 inhibitor for NSCLC.
Pembrolizumab was tested on patients with previously treated NSCLC with PD-L1 expression on at least 1% of tumor cells. These patients were randomized to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel every 3 weeks. The median OS was significantly longer for patients receiving pembrolizumab (10.4 months in the 2 mg/kg group and 12.7 months in the 10 mg/kg group vs 8.5 months in the docetaxel group). Overall, this trial found that pembrolizumab was relatively well tolerated and effective in patients with previously treated NSCLC with PD-L1 expression. The 22C3 clone of PD-L1 detection by immunohistochemical analysis was also approved as a diagnostic test to identify tumors with PD-L1 expression. 22 In 2015, nivolumab was approved for nonsquamous NSCLC after a phase 3 trial that found an increase of 3.2 months in OS and a 17% improvement in 2-year survival for patients with metastatic squamous NSCLC who had progressed while receiving platinumbased chemotherapy. 23 In another randomized study, nivolumab had superior clinical benefit to docetaxel in patients with nonsquamous NSCLC. The FDA approved nivolumab for nonsquamous NSCLC and also a complementary test for PD-L1 by immunohistochemical analysis to guide physicians for nivolumab treatment. 24 Atezolizumab is a PD-L1 inhibitor approved for the treatment of patients with metastatic NSCLC whose disease progressed during or after platinum-containing chemotherapy. Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations before receiving atezolizumab. This approval was based on the results of 2 international trials (OAK and POPLAR) testing more than 1100 patients. Atezolizumab was safe and efficacious, with a 4.2-month improved survival in patients in the OAK trial and a 2.9-month improved survival in the POPLAR trial. 25, 26 PD-1/PD L-1 Inhibitors in Genitourinary Malignancies Atezolizumab, an antiePD-L1 inhibitor, was proved to be safe and effective in advanced urothelial carcinoma. Compared with chemotherapy, the response was rapid and durable, and these results lead to accelerated FDA approval of the drug in metastatic urothelial carcinoma. 39 However, atezolizumab was not associated with significantly longer OS than was chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1. 40 In a large phase 2 study, nivolumab was tried on 270 patients with locally advanced or metastatic urothelial carcinoma who had progressed while receiving platinum-based chemotherapy. The OR was 19.6%, and, based on this study, nivolumab was granted accelerated approval for use in locally advanced or metastatic urothelial carcinoma who progress during or after platinum-based chemotherapy for metastatic disease or those who have disease progression within 1 year of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 28 Seventeen patients with castration-resistant prostate cancer were treated with nivolumab in an early-phase trial, but no objective response was noted. 41 Durvalumab was approved for locally advanced or metastatic urothelial carcinoma who progressed during or after treatment with platinum-based chemotherapy or those who progressed within 1 year of neoadjuvant or adjuvant therapy with platinum-based chemotherapy based on a trial of 191 patients who had an OR rate of 18% and median OS of 18.2 months. 27 Avelumab was found to be safe and efficacious in 44 patients with metastatic urothelial Pembrolizumab has been studied in patients ineligible for cisplatin, with successful results leading to FDA approval for use in this cohort. Three hundred seventy-four patients were enrolled in the study, and the OR rate was 29%. In a phase 3 trial on 542 patients who had recurred or progressed while receiving platinum-based chemotherapy, the OR and median OS rates were increased in the pembrolizumab group compared with the chemotherapy group. This lead to accelerated approval of the drug in locally advanced or metastatic urothelial carcinoma in patients who progressed during or after treatment with platinum-based chemotherapy or those who progressed within 1 year of neoadjuvant or adjuvant therapy with platinum-based chemotherapy. 30 A large multicenter trial assessed 821 patients with advanced RCC who progressed after at least 1 antiangiogenic therapy. These patients were randomized to receive nivolumab or everolimus. The OR and median OS rates were superior in patients receiving nivolumab vs everolimus (25% vs 5% and 25 months vs 19.6 months), leading to FDA approval of the drug for use in advanced RCC who progressed after at least 1 antiangiogenic therapy. 31 
PD-1 Inhibitors in Lymphoma
Nivolumab has been FDA approved for the treatment of relapsed or refractory classic Hodgkin lymphoma that has progressed after autologous stem cell transplant and posttransplant brentuximab vedotin. The approval was based on 2 trials in which nivolumab had a good response rate and tolerability profile. 32 Pembrolizumab was approved for the treatment of relapsed or refractory classic Hodgkin lymphoma after failure of at least 3 previous lines of therapy. The approval was based on a phase 2 trial in which 210 patients (69%) experienced a response. 33, 34 
PD-1 Inhibitors in Gastric Cancer
The FDA recently approved pembrolizumab for use in locally advanced or metastatic gastric or gastroesophageal junction cancer with positive PD-L1 expression based on a phase 2 trial of 259 patients who had progressed while receiving at least 2 chemotherapy regimens. These patients had a response rate of 13.3%, and pembrolizumab was tolerated well. 42 
PD-1 Inhibitors in Hepatobiliary Cancer
Nivolumab was approved for use in patients with advanced hepatocellular carcinoma who had progressed on or were intolerant of sorafenib. This approval followed the results of a trial that found that nivolumab was well tolerated and that the OR rate was 20% in patients with hepatocellular carcinoma. 35 
PD-1 Inhibitors in Colorectal Cancer
Pembrolizumab was evaluated in a phase 2 study of 28 patients with colorectal cancer with DNA mismatch repair (MMR) abnormalities and 25 patients with proficient MMR. Whereas the OR rate was 50% in the DNA MMR group, it was 0% in those with proficient MMR. The FDA granted accelerated approval of pembrolizumab for use in patients with advanced microsatellite instability or DNA MMR metastatic colorectal carcinoma who progressed while receiving conventional chemotherapy. 36 
PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma
Pembrolizumab was approved for use in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) progressing during/ after platinum-based chemotherapy. In a trial enrolling 174 patients with HNSCC, the OR rate was reported to be 16%, and 59% of patients were alive after 6 months. 43 Nivolumab was evaluated in 361 patients with HNSCC. These patients were randomized to receive either nivolumab or single-agent therapy of the investigators' choice. The OS rate was significantly longer in those receiving nivolumab (7.5 months vs 5.1 months), and the OR rate was also higher in the nivolumab group (13.3% vs 5.8%). Nivolumab was granted FDA approval based on these results. 37 
PD-1 Inhibitors in Merkel Cell Carcinoma
Avelumab was granted approval for use in Merkel cell carcinoma after a trial enrolling 88 patients reported an OR in 28 patients and 69% OS at 6 months. 38 
OTHER MONOCLONAL ANTIBODIES APPROVED FOR CANCER THERAPY
Monoclonal antibodies approved for treatment in cancer are summarized in Table 2 . Rituximab was one of the first antibodies to be used in the treatment of cancer. Combined with fludarabine and cyclophosphamide, it has achieved longer periods of survival in lymphoma. Studies have found that when added to the standard regimen for B-cell lymphoma, 70% of patients achieved complete remission vs 40% to those who received standard treatment only. 62 Trastuzumab blocks human epidermal growth factor receptor 2 signaling required for the growth of cancerous cells. When trastuzumab is added to the standard chemotherapeutic regimen, it increases disease-free survival by 10%. 63 As more patients are being treated with immunotherapy, there will be more patients who are at risk for toxicities due to these drugs. The incidence of these adverse effects varies depending on the agent used. Table 3 summarizes the commonly seen adverse effects of checkpoint inhibitors and their management according to the grade of adverse effect. The most commonly seen adverse effects involve the skin, colon, endocrine organs, and liver. As mentioned in Table 3 , most of the immunerelated adverse effects are treated with corticosteroids. There are several FDA-approved drugs in the market to treat immune-related diseases, such as rheumatoid arthritis, ulcerative colitis, and Crohn disease. These drugs would specifically target the immunologic consequences of immunotherapeutic agents without interfering with their anticancer activity. We propose that these drugs could be used to address the immune-related adverse effects of newer immunotherapeutic agents.
Infliximab (tumor necrosis factor [TNF]-a inhibitor) was used in the clinic successfully to treat severe or corticosteroid-refractory colitis due to immunotherapy. [64] [65] [66] A recent case series reported successful treatment of checkpoint-related colitis with vedolizumab (integrin inhibitor). 67 Similarly, another case series reported the use of tocilizumab (interleukin [IL]-6 inhibitor) in immunotherapyinduced arthritis. 68 Studies reported that many patients needed additional immunosuppression (TNF-a inhibitors, azathioprine, mycophenolate mofetil, tacrolimus) after corticosteroids to manage immune-related adverse effects. [69] [70] [71] [72] It would be interesting to try other TNF-a inhibitors, IL inhibitors, and integrin inhibitors to manage immune-related adverse effects. Table 4 describes the biological agents that are used for immune-related diseases and their possible use in treating immune-related consequences of cancer immunotherapy.
ADOPTIVE CELL THERAPY
Adoptive cell therapy (ACT) aims to fight cancer with the use of lymphocytes, usually a mixture of CD8 and CD4 cells. Theoretically it is an ideal modality of cancer treatment because T cells develop tumor-specific immune response, retain memory, and can launch a robust response. Lymphocytes are isolated from the patient's blood, tumor, and draining lymph nodes. They are then cultured, expanded ex vivo, and infused back into the patient's bloodstream. Figure 3 describes the concept of ACT. Some of the different types of ACT are tumor-infiltrating lymphocytes (TILs), antigen-specific autologous T-cell clones, donor antitumor lymphocytes, and, more recently, genetically engineered human lymphocytes. 80 In a landmark publication, 86 patients with melanoma were treated with either TIL or high-dose IL-2 over 5 years. The OR in the TIL group was 36%, and 5 patients had a complete response. 81 Several trials in patients with melanoma have reported a sustained durable response with TIL, especially when it is preceded by a lymphodepletion conditioning regimen. The phase of lymphodepletion eliminates immunosuppressive cells such as regulatory T cells and increases the availability of local cytokines. 82, 83 Rosenberg et al 84 enrolled 93 patients with metastatic melanoma refractory to standard therapy. The patients were exposed to cytotoxic chemotherapy that causes lymphodepletion. The OR ranged from 49% to 72%. Complete regression of tumor was seen in 20 patients. The response was more favorable in patients with greater lymphodepletion. 84 Although ACT relies on endogenous T-cell repertoire, recent advances in biotechnology allow induction of tumor-specific T-cell receptors or chimeric antigen receptors (CARs). The CARs exhibit high-affinity major histocompatibility complex independent recognition of any antigen. 85 In CAR T-cell (CAR-T) therapy, T cells of patients with B-cell tumors are transfected with anti-CD19 and, thus, they gain the capacity to recognize B cells in all stages of development. The recently developed CAR-Ts are designed to have an extracellular domain that recognizes CD19 and an intracellular domain that stimulates production of cytokines. 86 The first CAR-T was approved recently. This FDA approval was based on the results of an open-label, multicenter, single-arm, phase 2 trial in which 68 patients with acute lymphoblastic leukemia were infused with CAR-T, and results were assessed in 63 patients. The results showed a dramatic complete response in 83% of patients within 3 months of infusion. The median duration of response was not reached. The most common adverse reactions were cytokine release syndrome, hypogammaglobulinemia, infections, pyrexia, and decreased appetite. 87 ACT carries a risk of infection and is expensive and timeconsuming. 88 Identifying the ideal tumor antigen, the cost, and the difficulty of the procedure have made this modality less popular.
CYTOKINES
Interferons (IFNs) possess antiviral and immunomodulatory properties. 89 High-dose IFN-a is approved for hairy cell leukemia, malignant melanoma, FL, and Kaposi sarcoma. It was first tried in hairy cell leukemia and other lymphoproliferative and myeloproliferative neoplasms. Applying recombinant DNA technology, we have been able to produce recombinant IFN-a2b. Also, conjugation with polyethylene glycol (PEG) reduces toxicity of IFN. Efficacy is not altered by these modifications, but adverse effects are reduced. Treatment with IFN is associated with fever, flulike symptoms, chills, headaches, local reactions, and, rarely, hypotension, arrhythmia, confusion, and gastrointestinal distress.
Use of PEG-IFN-a2b in high-risk melanoma is approved by the FDA. This approval was based on a large trial involving 1256 patients after surgical resection. The patients were randomized 1:1 in the PEG-IFN group and the other observation group. The PEG-IFN, 6 mg/kg per week, was administered subcutaneously for 8 doses, followed by 3 mg/ kg per week for up to 252 weeks. The median RFS times were 34.8 months in the group receiving PEG-IFN and 25.5 months in the observation group. 90 Interleukin-2 is one of the key cytokines in the immune system with various effects mainly related to T-cell activation. It enhances cellular immunity through increasing white cells, eosinophils, and multiple cytokines. Aldesleukin, a recombinant IL-2, is a potent immunostimulator. 91 High-dose IL-2 is indicated in metastatic renal cell carcinoma and melanoma. Highdose IL-2 was used in 255 patients with metastatic RCC, and the overall response rate was observed to be 14%. 92 Similarly, 270 patients with metastatic melanoma had an OR rate of 16%. 93 A recent analysis including 170 patients with metastatic melanoma and 192 patients with metastatic RCC treated with high-dose IL-2 was reported. In patients with melanoma, complete response was observed in 5%, partial response in 10%, stable disease in 22%, and progressive disease in 63%. The median OS for these patients was 19.6 months, and in patients with metastatic RCC the median OS was 41 months. 94 Some of the adverse effects associated with IL-2 are capillary leak syndrome, hypotension, infections, and local reactions. 95 
VACCINES
After decades of hard work and struggle, anticancer vaccines are now a reality. The FDA has approved vaccines to fight melanoma and prostate cancer. Numerous newer vaccines are being developed every day for different cancers.
One of the toughest challenges in developing a vaccine is finding the ideal antigen. An ideal vaccine target antigen should be specifically expressed on tumor tissue, processed as peptide major histocompatibility complex class 1 complexes and easy to produce and administer. An anticancer vaccine should be able to stimulate dendritic cell (DC) maturation and promote the production of tumorspecific, CD8
þ cytotoxic T cells.
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FIGURE 3. The concept of adoptive cell therapy.
Initially, short peptide vaccines were used as target antigens. Unfortunately, they could not be developed as vaccines in the clinic due to poor pharmacokinetic properties and poor efficacy. Then, recombinant proteins were created. Melanoma antigen family A3 is an antigen expressed on melanoma, NSCLC, and various hematologic malignancies. 97 It, however, was not efficacious when tried in clinical trials. Cell-based vaccines were then tried as cancer vaccine antigens. 98 An example of a whole tumor cell vaccine modified to produce cytokines is GVAX, which was tried in pancreatic cancer, but phase 3 was halted due to lack of vaccine efficacy. 99 The DCs are antigen-presenting cells that play a vital role in triggering an immune response. One school of thought suggested that the use of high quantities of antigens targeting the DCs could be used to break the tolerance developed by cancer cells. 98 To prepare DC vaccines, DCs are collected from the patient's blood, treated with tumor antigens and maturation stimuli, and then reinfused back into the patient. 100 Sipuleucel-T is a DC vaccine combined with prostatic acid phosphatase protein and granulocyte-macrophage colony-stimulating factor (GM-CSF). Studies have found a 4-month increase in median survival in prostate cancer due to this vaccine. It has been approved for use in prostate cancer by the FDA since 2010. 101 Preventive vaccines used in cancer immunology are human papilloma virus vaccine to prevent human papilloma viruseassociated cancers and hepatitis B virus vaccine to prevent hepatocellular carcinoma. 102, 103 Some vaccines have been tried but have not yielded successful results in clinical studies. Prostvac is a vaccine targeting prostatespecific antigen that was explored in the treatment of prostate cancer. 104, 105 Stimuvax is a vaccine containing CD4 and CD8 epitopes for proteoglycan expressed on several tumors. In a phase 2 trial, patients who received both the vaccine and best supportive care had median survival of 4.2 months higher than those who received best supportive care alone. 106 BiovaxID is a personalized vaccine developed from the patient's tissue biopsy that has given mixed results in follicular carcinoma. 107, 108 ONCOLYTIC VIRUS THERAPY Oncolytic viruses promote antitumor responses by infecting the tumor cell and initiating specific antitumor immunity. 109 Scientists have used viral genome to reduce its pathogenicity and augment antitumor responses. Covalent conjugation of the viral coat with PEG can prevent the host immune response from developing an antiviral response. 110 Genetic engineering also allows expression of desired cytokines to increase immune response. 111 After the virus infects the tumor cells, it causes cell lysis, releasing tumor cell antigens. A sustained, specific CD8 þ T-cellemediated response is developed against these tumor antigens.
Talimogene laherparepvec (T-VEC) is a genetically modified oncolytic herpes simplex virus type-1. The genes for neuronal development are deleted and the coding sequence for GM-CSF is added to it. 112 A phase 3 randomized controlled trial enrolling 439 patients with metastatic melanoma evaluated the efficacy of T-VEC. The patients were randomized into 2 arms at a ratio of 2:1 receiving T-VEC and GM-CSF, respectively. Better and durable responses were noted in patients of the T-VEC group. There were minimal adverse effects such as, fever, fatigue, nausea, and local site reaction. 113 The FDA approved T-VEC to treat advanced melanoma in October 2015. Also, T-VEC has been tried in combination with other treatment strategies. A phase 1 trial of T-VEC combined with ipilimumab in melanoma had an OR rate of 50%, and 44% of patients had durable responses at 6 months. 114 Talimogene laherparepvec was combined with chemoradiation for patients with HNSCC. At median follow-up of 29 months, locoregional control was 100% and RFS was 76%. 115 
FUTURE TRENDS IN IMMUNOTHERAPY
For most patients, monotherapy is not entirely effective and there is a need to have a combination of drugs. Although CTLA-4 and PD-1 work on different signaling pathways, both facilitate T-cell activation. Thus, the combination of antiePD-1 and antieCTLA-4 has shown synergy in the clinic. 98 In a recent randomized controlled phase 3 trial, the efficacy of monotherapy with either nivolumab or ipilimumab was compared with their combination, showing a greater response in the combination group. 116 Although this combination increased antitumor immunity, it also added to the immunologic adverse effects. Because it is a novel combination, the longterm consequences are still unknown. 117 Recently, the combination of chemoimmunotherapy is catching the attention of investigators. Chemotherapy can sensitize the tumor to immunotherapy in many ways. 118 Recently, the combination of pembrolizumab and chemotherapy (pemetrexed and carboplatin) was granted FDA approval for NSCLC. Vascular endothelial growth factor inhibitors have been tried in combination with immunotherapy. Hodi et al 119 used antieCTLA-4 inhibitors and bevacizumab and reported increased median OS of 25 months. Unfortunately, the inflammatory adverse effects were increased. 119 A myriad of possible combinations exist along with checkpoint blockers as the main stem. Not just combining but appropriate timing of different therapies is essential for optimal results.
A biomarker predicting the response to therapy would be a useful tool before initiating immunotherapy. It would help to identify the population that would benefit from treatment and prevent unnecessary cost and adverse effects in those who would not. 120 Higher mutational load was found to have a direct effect on response to therapy. 23, 121 Similar studies showed that lymphocytes infiltrate improved survival. 118 Expression of PD-L1 on tumors was a useful predictor for response to antiePD-1/PD-L1 therapy. 41 Furthermore, epigenetic drugs have been used to improve cancer immunoresponsivity. Epigenetic drugs such as DNA methyltransferases and histone deacetylases modify the expression of genes and reverse immune suppression through various mechanisms. Epigenetic drugs increase the expression of tumorassociated antigens, and the host immune system works with these drugs to better recognize tumors. These drugs also enhance the efficacy of checkpoint inhibitors when used in combination with them. 122 These drugs have been tried in combination with other agents for NSCLC, melanoma, and prostate and colon cancers in various clinical trials. Drugantibody conjugates consist of recombinant monoclonal antibodies covalently bound to cytotoxic chemicals via linkers. Modifications in linkages and warheads have led to improved drug delivery systems. After tumor cell lysis from drug antibody conjugates, more tumor antigens might be expressed to facilitate T-cell responses against the tumor. Preclinical studies have identified that antibody drug conjugates not only have cytotoxic effects but also stimulate the immune system. A strong synergistic effect is seen in combination with PD-1/PD-L1 inhibitors. 123 Nanoparticles have been used in various areas of medicine and science. Nanoparticles such as liposomes, dendrimers, micelles, polymer nanoparticles, nanotubes, and inorganic nanoparticles can all be used to deliver the desired agent. This method ensures optimal drug delivery and higher efficacy. Researchers are applying nanotechnology to cancer immunology to develop nanocarriers for vaccines and chemo-immunotherapies. 124 Tumorspecific antigens can be identified by techniques such as serological analysis of expression cDNA libraries (SEREX). Newly discovered antigens could be used as potential targets of immunotherapy. 125 
CONCLUSION
Over the years, our understanding of the immune system has greatly increased. Today, there are multiple approaches in cancer immunology, such as monoclonal antibodies, cytokines, vaccines, and ACT. Checkpoint inhibitors have revolutionized the field of immuno-oncology; however, they are associated with a range of unique immune-related adverse effects involving the skin, gastrointestinal system, lungs, endocrine system, and respiratory system. It is important to know about these adverse effects and management strategies of these adverse effects. Despite incredible progress in the field of immuno-oncology, there are still challenges that we face.
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